Skip to main content
OpenTrials

Clinical trial condition

Post-essential Thrombocythemia Myelofibrosis

Explore clinical trials studying Post-essential Thrombocythemia Myelofibrosis. Study availability and eligibility vary by location and protocol.

27 public trials 9 recruiting studies
Refine in advanced search Browse all conditions

Post-essential Thrombocythemia Myelofibrosis trial results

Completed

Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

NCT01423058

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +4 more
Locations
  • Mayo Clinic Scottsdale, Arizona, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • MD Anderson Cancer Center, The University of Texas Houston, Texas, United States
  • Huntsman Cancer Institute at the University of Utah Salt Lake City, Utah, United States
View Trial Details
Completed

Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

NCT01236638

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +4 more
Locations
  • Stanford Cancer Center Stanford, California, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Mayo Clinic Rochester, Minnesota, United States
  • The Royal Melbourne Hospital Parkville, Victoria, Australia
View Trial Details
Completed

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

NCT00935987

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +4 more
Locations
  • Stanford Cancer Center Stanford, California, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Mayo Clinic Rochester, Minnesota, United States
  • The Royal Melbourne Hospital Parkville, Victoria, Australia
View Trial Details
Active, Not Recruiting

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

NCT04603495

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers Chandler, Arizona, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • USC/Norris Comprehensive Cancer Center Los Angeles, California, United States
View all 156 locations
View Trial Details
Active, Not Recruiting

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

NCT04455841

Conditions
Anemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +2 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • City of Hope Orange County Irvine, California, United States
  • Usc Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Stanford Cancer Center Palo Alto, California, United States
View all 34 locations
View Trial Details
Active, Not Recruiting

Study of Canakinumab in Patients With Myelofibrosis

NCT05467800

Conditions
Bone Marrow Diseases, ET-MF, Hematologic Diseases, +6 more
Locations
  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute Los Angeles, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • The University of Kansas Cancer Center-Westwood Westwood, Kansas, United States
  • Ruttenberg Treatment Center New York, United States
View Trial Details
Active, Not Recruiting

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

NCT03165734

Conditions
Anemia, Blood Platelet Disorders, Bone Marrow Diseases, +11 more
Locations
  • University of Alabama at Birmingham, (UAB) Hospital, Comprehensive Cancer Center Birmingham, Alabama, United States
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • City of Hope Duarte, California, United States
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
View all 207 locations
View Trial Details

Related conditions